Pieris Pharmaceuticals Inc (OQ:PIRS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 225 Franklin Street, 26Th Floor
BOSTON MA 02110
Tel: N/A
Website: https://www.pieris.com
IR: See website
<
Key People
Stephen S. Yoder
President, Chief Executive Officer, Director
Thomas Bures
Chief Financial Officer, Senior Vice President
Hitto Kaufmann
Senior Vice President, Chief Scientific Officer
Shane Olwill
Senior Vice President, Chief Development Officer
   
Business Overview
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company's clinical pipeline includes an inhaled IL-4Ra antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin based drug candidate, elarekibep, antagonizes IL-4Ra, thereby inhibiting IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. Its IO portfolio also includes additional drug candidates beyond PRS-344/S095012 that are multi-specific Anticalin-based fusion proteins designed to engage immunomodulatory targets, comprising a variety of multifunctional biotherapeutics.
Financial Overview
For the nine months ended 30 September 2023, Pieris Pharmaceuticals Inc revenues increased from $20.1M to $41.5M. Net loss decreased 21% to $20M. Revenues reflect Customer revenue increase of 91% to $37.7M, Collaboration revenue increase from $296K to $3.8M. Lower net loss reflects Research and development decrease of 6% to $37.3M (expense), Interest income increase from $373K to $1.4M (income).
Employees: 127 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $47.36M as of Sep 30, 2023
EBITDA (TTM): -$12.40M as of Sep 30, 2023
Net annual income (TTM): -$28.06M as of Sep 30, 2023
Free cash flow (TTM): -$47.26M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 98,851,927 as of Nov 9, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.